TYP — Tryptamine Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$40.85m
- AU$38.02m
- AU$1.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.64 | ||
| Price to Tang. Book | 10.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 38.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -187.74% | ||
| Return on Equity | -246.25% | ||
| Operating Margin | -743.39% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.73 | 4.2 | 4.21 | 3.41 | 1.12 | n/a | n/a | 107.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.
Directors
- Jason Watson NEC
- Ian Dixon FDR
- Gregor Lichtfuss COO
- Chris Baldwin OTH
- Alison Cook OTH
- David Franks SEC
- Jennifer King DRC
- Elizabeth McGregor NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 15th, 2013
- Public Since
- December 18th, 2018
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,276,421,906
- Address
- C/o Bio101 Financial Advisory Pty Ltd, MELBOURNE, 3124
- Web
- https://exopharm.com/
- Phone
- +61 384190827
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for TYP
Similar to TYP
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Tryptamine Therapeutics share price?
As of Today at 23:48 UTC, shares in Tryptamine Therapeutics are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Tryptamine Therapeutics share price performed this year?
Shares in Tryptamine Therapeutics last closed at AU$0.03 and the price had moved by +190.91% over the past 365 days. In terms of relative price strength the Tryptamine Therapeutics share price has outperformed the ASX All Ordinaries Index by +180.37% over the past year.
What are the analyst and broker recommendations for Tryptamine Therapeutics?
The overall consensus recommendation for Tryptamine Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tryptamine Therapeutics dividend yield?
Tryptamine Therapeutics does not currently pay a dividend.
Does Tryptamine Therapeutics pay a dividend?
Tryptamine Therapeutics does not currently pay a dividend.
When does Tryptamine Therapeutics next pay dividends?
Tryptamine Therapeutics does not currently pay a dividend.
How do I buy Tryptamine Therapeutics shares?
To buy shares in Tryptamine Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tryptamine Therapeutics?
As of the previous close price of AU$0.03, shares in Tryptamine Therapeutics had a market capitalisation of AU$40.85m.
Where are Tryptamine Therapeutics shares listed?
Here are the trading details for Tryptamine Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: TYP
What kind of share is Tryptamine Therapeutics?
Based on an overall assessment of its quality, value and momentum Tryptamine Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tryptamine Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Tryptamine Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tryptamine Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -0.25%.
As of the last closing price of AU$0.03, shares in Tryptamine Therapeutics were trading +3.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tryptamine Therapeutics PE Ratio?
The Tryptamine Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tryptamine Therapeutics?
Tryptamine Therapeutics' management team is headed by:
- Jason Watson - NEC
- Ian Dixon - FDR
- Gregor Lichtfuss - COO
- Chris Baldwin - OTH
- Alison Cook - OTH
- David Franks - SEC
- Jennifer King - DRC
- Elizabeth McGregor - NED